Cholera Clinical Trial
Official title:
A Phase III Randomized, Double-blind, Placebo-controlled Study in Older Adults to Assess Immunogenicity and Clinical Acceptability of a Single-dose of the Live Oral Cholera Vaccine Candidate PXVX0200 O1 Serotype Inaba Strain CVD 103-HgR
NCT number | NCT02100631 |
Other study ID # | PXVX-VC-200-005 |
Secondary ID | |
Status | Completed |
Phase | Phase 3 |
First received | |
Last updated | |
Start date | May 2014 |
Est. completion date | June 2015 |
Verified date | June 2023 |
Source | Bavarian Nordic |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Demonstrate that the vaccine offers protection based on antibody levels in older adults and is similar to antibody levels in adults aged 18-45 following vaccination with PXVX0200.
Status | Completed |
Enrollment | 398 |
Est. completion date | June 2015 |
Est. primary completion date | February 2015 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 46 Years to 64 Years |
Eligibility | Inclusion Criteria: 1. Able to understand the study and give written consent. 2. Healthy male and female adults, age 46-64 years (inclusive) without significant medical history, physical, or abnormal screening laboratory test results at screening. 3. Women of childbearing potential must have had a negative urine pregnancy test at screening, prior to vaccination. Female subjects must be of non-childbearing potential (as defined as surgically sterile or postmenopausal for more than 1 year), or if of childbearing potential must be practicing abstinence or using an effective licensed method of birth control (eg, use hormonal or barrier birth control such as implants, injectables, combined oral contraceptives, intrauterine devices [IUDs], cervical sponges, diaphragms, condoms with spermicidal agents; or must have a vasectomized partner) within 2 months of vaccination and must agree to continue such precautions during the study. 4. Willing and able to comply with the study requirements and procedures. Exclusion Criteria: 1. Currently active unstable or undiagnosed medical conditions including immunodeficiency, cardiovascular disease, respiratory disease, endocrine disorder, liver disease, renal disease, gastrointestinal disease, neurologic illness, psychiatric disorder requiring hospitalization, current drug or alcohol abuse. Examples of unstable or undiagnosed medical conditions including unstable angina pectoris, shortness of breath on exertion without clear etiology and chronic renal failure requiring dialysis. Examples of conditions that do not meet exclusion criteria include mild controlled hypertension, mild controlled asthma, and treated depression without hospitalization. 2. Abnormal stool pattern defined as fewer than 3 stools per week or more than 2 stools per day in past 6 months. 3. Regular use of laxatives in the past 6 months. 4. Previously received a licensed or investigational cholera vaccine. 5. History of cholera or enterotoxigenic E. coli infection (natural infection or experimental challenge). 6. Travel to a cholera-endemic area in the previous 5 years. 7. Received or plans to receive any other licensed vaccines, except for seasonal influenza vaccine, from 14 days prior to the study vaccination through to 29 days after vaccination. 8. Received or plans to receive antibiotics or chloroquine within 14 days prior to the study vaccination through to 29 days after vaccination. 9. Recipient of bone marrow or solid organ transplant. 10. Use of systemic chemotherapy in the previous 5 years prior to the study. 11. Malignancy (excluding non-melanotic skin cancers) or lymphoproliferative disorders diagnosed or treated during the past 5 years. 12. Received or plans to receive systemic immunosuppressive therapy, radiation therapy, parenteral or high-dosage inhaled steroids (>800 µg/day of beclomethasone diproprionate or equivalent) within 6 months prior to the study vaccination through to Day 29. 13. History of Guillain-Barré Syndrome. 14. Pregnant or nursing. |
Country | Name | City | State |
---|---|---|---|
United States | Emory University | Atlanta | Georgia |
United States | Boston University | Boston | Massachusetts |
United States | University of Vermont | Burlington | Vermont |
United States | Research Across America | Dallas | Texas |
United States | Avail Clinical | DeLand | Florida |
United States | Center for Pharmaceutical Research | Kansas City | Missouri |
United States | Johnson County Clin-Trials | Lenexa | Kansas |
United States | Central Kentucky Research | Lexington | Kentucky |
United States | University of Kentucky | Lexington | Kentucky |
United States | Miami Research Associates | Miami | Florida |
United States | Coastal Clinical Research | Mobile | Alabama |
United States | Coastal Carolina Research | Mount Pleasant | South Carolina |
United States | Palm Beach Research Center | Palm Beach | Florida |
United States | St. Louis University | Saint Louis | Missouri |
United States | Jean Brown Research | Salt Lake City | Utah |
United States | Heartland Research | Wichita | Kansas |
Lead Sponsor | Collaborator |
---|---|
Bavarian Nordic | Emergent BioSolutions |
United States,
McCarty JM, Lock MD, Bennett S, Hunt KM, Simon JK, Gurwith M. Age-related immunogenicity and reactogenicity of live oral cholera vaccine CVD 103-HgR in a randomized, controlled clinical trial. Vaccine. 2019 Mar 7;37(11):1389-1397. doi: 10.1016/j.vaccine.2 — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Cumulative Seroconversion Through Day 29 Compared to Day 11 for Younger Adults | The cumulative seroconversion through Day 29 for older adults was compared to the Day 11 seroconversion for the younger adults aged 18 - 45 yrs. Seroconversion is defined as a 4-fold rise in antibody titer relative to baseline values. | Day 29 | |
Other | Mean Fold Change in Vibriocidal Antibody Titer Between Day 1 and Day 11 | The mean log2 fold change between Day 1 and Day 11 in classical Inaba vibriocidal antibody titer attained by older adults was compared to the younger adults aged 18 - 45 yrs. | Day 11 | |
Other | Seroconversion Against Other V. Cholerae Biotypes/Serotypes | Seroconversion of the vibriocidal antibody response against 4 V. cholerae biotypes/serotypes - classical Inaba, El Tor Inaba, classical Ogawa and El Tor Ogawa was assessed. | Day 11 | |
Other | Anti-CT Antibody Response in Older Adults | The seroconversion of anti-Cholera Toxin (CT) antibody response in older adults was assessed.
Seroconversion is defined as a 4-fold rise in anti-CT antibody titer relative to baseline values. |
Day 11 | |
Primary | Seroconversion Rate at Day 11 | The seroconversion rate is defined as the percentage of subjects with a 4-fold or greater rise over baseline Day 1 Serum Vibriocidal Antibody (SVA) titer against the classical Inaba biotype of V. cholerae at Day 11 following one dose of Vaxchora vaccine. The hypothesis was that the seroconversion rate would be non-inferior to the seroconversion rate at Day 11 in adults between the ages of 18 and 45 years. | Day 11 | |
Secondary | Geometric Mean Titer (GMT) | The Day 11 vibriocidal GMTs were compared between older and younger adults. | Day 11 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01895855 -
Safety and Efficacy Challenge Study of Live Oral Cholera Vaccine Candidate,PXVX0200, to Prevent Cholera
|
Phase 3 | |
Completed |
NCT01339845 -
Introduction of Cholera Vaccine in Bangladesh
|
N/A | |
Recruiting |
NCT05829772 -
Impact Study of Cholera Vaccination in Endemic Areas - Seroprevalence
|
||
Completed |
NCT04760236 -
Immune Non-Inferiority, Safety and Lot-to-Lot Consistency of Oral Cholera Vaccine-Simplified Compared to Shanchol™
|
Phase 3 | |
Recruiting |
NCT04326478 -
Single Dose Azithromycin to Prevent Cholera in Children
|
Phase 2 | |
Recruiting |
NCT06104345 -
Immune Response Elicited by Concomitant Administration of Oral Typhoid Fever (Vivotif®) and Cholera (Dukoral®) Vaccines
|
Phase 4 | |
Completed |
NCT02928341 -
Impact Evaluation of Urban Water Supply Improvements on Cholera and Other Diarrhoeal Diseases in Uvira, Democratic Republic of Congo
|
N/A | |
Completed |
NCT02864433 -
Evaluation of a Pilot Program to Introduce Cholera Vaccine in Haiti as Part of Global Cholera Control Efforts
|
||
Recruiting |
NCT06003816 -
Cholera-Hospital-Based-Intervention-for-7-Days (CHoBI7) Water, Sanitation, and Hygiene (WASH) Case Area Targeted Intervention (CATI)
|
N/A | |
Not yet recruiting |
NCT05771779 -
Co-administration Study of OCV, TCV and MR
|
Phase 3 | |
Not yet recruiting |
NCT06455852 -
Correlates of Protection for Cholera
|
N/A | |
Completed |
NCT04150250 -
Cholera Anti-Secretory Treatment Trial
|
Phase 2 | |
Terminated |
NCT00624975 -
Safety and Immunogenicity of Peru-15 Vaccine When Given With Measles Vaccine in Healthy Indian and Bangladeshi Infants
|
Phase 2 | |
Completed |
NCT00226616 -
Zinc Supplementation in Cholera Patients
|
Phase 3 | |
Completed |
NCT03373669 -
Effect of Extended Dose Intervals on the Immune Response to Oral Cholera Vaccine
|
Phase 4 | |
Completed |
NCT02094586 -
A Phase 3 Lot to Lot Consistency Study of Live Oral Cholera Vaccine, PXVX0200 in Healthy Adults
|
Phase 3 | |
Completed |
NCT01823939 -
PK Study of iOWH032 in Adult Male/Female Healthy Volunteers & Adult Males With Cholera
|
Phase 1 | |
Completed |
NCT01365442 -
Pilot Introduction of Oral Cholera Vaccine in Orissa, India
|
N/A | |
Completed |
NCT00128011 -
Safety and Immunogenicity of a New Formulation of a Bivalent Killed, Whole-Cell Oral Cholera Vaccine
|
Phase 2 | |
Completed |
NCT00672308 -
Efficacy of Benefiber-Added, Reduced-Osmolarity WHO-ORS in the Treatment of Cholera in Adults
|
Phase 2 |